Pacmilimab

DB18873InvestigationalProtein Based Therapies

Pacmilimab is under investigation in clinical trial NCT04596150 (Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer).

Mechanism: Pharmacologically active on Programmed cell death 1 ligand 1
Curator reviewed
Also known as: Cx-072 probody · IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH-LIGAND 1) (HUMAN MONOCLONAL CX-072 .GAMMA.4-CHAIN), DISULFIDE WITH PRODOMAIN PROTEIN (SYNTHETIC MASKING MOIETY AND CLEAVABLE MOIETY PROTEASE SUBSTRATE-CONTAINING) FUSION PROTEIN WITH HUMAN MONOCLONAL C · Protease-activated anti-pd-l1 antibody prodrug cx-072
Code names: CX-072

Resolves to

Compound

UNIIZXP96ZI2RACAS2145091-51-4

Targets

Q9NZQ7CD274

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pacmilimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account